Gordon A Francis

List of Publications by Year
in descending order

61 papers	6,432 citations	117625 34 h-index	133252 59 g-index
61 all docs	61 docs citations	61 times ranked	8129 citing authors

#	Article	IF	Citations
1	Autophagy in Atherosclerosis: Not All Foam Cells Are Created Equal. Circulation Research, 2022, 130, 848-850.	4.5	3
2	Low LAL (Lysosomal Acid Lipase) Expression by Smooth Muscle Cells Relative to Macrophages as a Mechanism for Arterial Foam Cell Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, e354-e368.	2.4	23
3	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Canadian Journal of Cardiology, 2021, 37, 1129-1150.	1.7	367
4	Lipid-lowering therapy for primary prevention of premature atherosclerotic coronary artery disease: Eligibility, utilization, target achievement, and predictors of initiation. American Journal of Preventive Cardiology, 2020, 2, 100036.	3.0	4
5	Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2020, 75, 2682-2693.	2.8	50
6	High prevalence of plasma lipid abnormalities in human and canine Duchenne and Becker muscular dystrophies depicts a new type of primary genetic dyslipidemia. Journal of Clinical Lipidology, 2020, 14, 459-469.e0.	1.5	18
7	Smooth Muscle Cell-Proteoglycan-Lipoprotein Interactions as Drivers of Atherosclerosis. Handbook of Experimental Pharmacology, 2020, , 1.	1.8	7
8	Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2019, 74, 512-522.	2.8	121
9	Low Rates of Identification and Treatment of Familial Hypercholesterolemia in France and Elsewhere: A Call for Universal Screening. Canadian Journal of Cardiology, 2019, 35, 699-700.	1.7	0
10	Smooth Muscle Cells Contribute the Majority of Foam Cells in ApoE (Apolipoprotein E)-Deficient Mouse Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 876-887.	2.4	199
11	Pathways of smooth muscle foam cell formation in atherosclerosis. Current Opinion in Lipidology, 2019, 30, 117-124.	2.7	46
12	Multiplexed LCâ€"ESIâ€"MRMâ€MSâ€based Assay for Identification of Coronary Artery Disease Biomarkers in Human Plasma. Proteomics - Clinical Applications, 2019, 13, 1700111.	1.6	8
13	Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors. Canadian Journal of Cardiology, 2018, 34, 1004-1009.	1.7	24
14	The design and rationale of SAVE BC: The Study to Avoid CardioVascular Events in British Columbia. Clinical Cardiology, 2018, 41, 888-895.	1.8	11
15	Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovascular Research, 2018, 114, 540-550.	3.8	322
16	LAL (Lysosomal Acid Lipase) Promotes Reverse Cholesterol Transport In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1191-1201.	2.4	24
17	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Clinical Chemistry, 2018, 64, 355-362.	3.2	47
18	Nonfasting lipid testing: the new standard for cardiovascular risk assessment. Cmaj, 2018, 190, E1317-E1318.	2.0	15

#	Article	IF	Citations
19	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Canadian Journal of Cardiology, 2018, 34, 1553-1563.	1.7	105
20	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. Atherosclerosis, 2018, 277, 419-424.	0.8	18
21	Simplified Canadian Definition for Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1210-1214.	1.7	62
22	Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: AÂProspective Observational Study. Canadian Journal of Cardiology, 2017, 33, 385-392.	1.7	25
23	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2016, 32, 1263-1282.	1.7	775
24	So Much Cholesterol. Current Opinion in Lipidology, 2016, 27, 155-161.	2.7	65
25	Colesevelam as an Add-On Treatment for Control of Dyslipidemia and Hyperglycemia in Type 2 Diabetes. Canadian Journal of Diabetes, 2016, 40, 112-114.	0.8	5
26	Lysosomal acid lipase: at the crossroads of normal and atherogenic cholesterol metabolism. Frontiers in Cell and Developmental Biology, 2015, 3, 3.	3.7	102
27	Efficacy and safety of rosuvastatin therapy inÂchildren and adolescents with familial hypercholesterolemia: Results from the CHARONÂstudy. Journal of Clinical Lipidology, 2015, 9, 741-750.	1.5	42
28	Response to Letter Regarding Article, â€œContribution of Intimal Smooth Muscle Cells to Cholesterol Accumulation and Macrophage-Like Cells in Human Atherosclerosisâ€. Circulation, 2015, 131, e25.	1.6	3
29	Targeted next-generation sequencing to diagnose disorders of HDL cholesterol. Journal of Lipid Research, 2015, 56, 1993-2001.	4.2	28
30	Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel. Canadian Journal of Cardiology, 2014, 30, 377-380.	1.7	27
31	Contribution of Intimal Smooth Muscle Cells to Cholesterol Accumulation and Macrophage-Like Cells in Human Atherosclerosis. Circulation, 2014, 129, 1551-1559.	1.6	493
32	Oxysterol generation and liver X receptor-dependent reverse cholesterol transport: Not all roads lead to Rome. Molecular and Cellular Endocrinology, 2013, 368, 99-107.	3.2	33
33	2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2013, 29, 151-167.	1.7	680
34	Contribution of monocyte-derived macrophages and smooth muscle cells to arterial foam cell formation. Cardiovascular Research, 2012, 95, 165-172.	3.8	136
35	ABCA1-dependent mobilization of lysosomal cholesterol requires functional Niemannâ€“Pick C2 but not Niemannâ€“Pick C1 protein. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 396-404.	2.4	37
36	Lysosomal Acid Lipase Deficiency Impairs Regulation of ABCA1 Gene and Formation of High Density Lipoproteins in Cholesteryl Ester Storage Disease. Journal of Biological Chemistry, 2011, 286, 30624-30635.	3.4	79

#	Article	IF	Citations
37	The complexity of HDL. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 1286-1293.	2.4	56
38	Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS). Canadian Journal of Cardiology, 2010, 26, e330-e335.	1.7	46
39	The National Niemann-Pick Type C1 Disease Database: correlation of lipid profiles, mutations, and biochemical phenotypes. Journal of Lipid Research, 2010, 51, 406-415.	4.2	84
40	ATP-Binding Cassette Transporter A1 Expression and Apolipoprotein A-I Binding Are Impaired in Intima-Type Arterial Smooth Muscle Cells. Circulation, 2009, 119, 3223-3231.	1.6	88
41	Physiological and coordinate downregulation of the NPC1 and NPC2 genes are associated with the sequestration of LDLâ€derived cholesterol within endocytic compartments. Journal of Cellular Biochemistry, 2009, 108, 1102-1116.	2.6	10
42	2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult â€" 2009 recommendations. Canadian Journal of Cardiology, 2009, 25, 567-579.	1.7	653
43	The Niemann-Pick C1 gene is downregulated by feedback inhibition of the SREBP pathway in human fibroblasts. Journal of Lipid Research, 2008, 49, 1090-1102.	4.2	31
44	Cellular cholesterol substrate pools for adenosine-triphosphate cassette transporter A1-dependent high-density lipoprotein formation. Current Opinion in Lipidology, 2008, 19, 270-276.	2.7	25
45	The National Niemannâ€"Pick C1 disease database: Report of clinical features and health problems. American Journal of Medical Genetics, Part A, 2007, 143A, 1204-1211.	1.2	158
46	Peroxisomal proliferator activated receptor-Î³ deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Medical Genetics, 2006, 7, 3.	2.1	54
47	The role of vesicular transport in ABCA1-dependent lipid efflux and its connection with NPC pathways. Journal of Molecular Medicine, 2006, 84, 266-275.	3.9	37
48	Correction of Apolipoprotein A-I-mediated Lipid Efflux and High Density Lipoprotein Particle Formation in Human Niemann-Pick Type C Disease Fibroblasts. Journal of Biological Chemistry, 2006, 281, 37081-37090.	3.4	39
49	Generation and function of astroglial lipoproteins from Niemannâ€"Pick typeÂC1-deficient mice. Biochemical Journal, 2005, 387, 779-788.	3.7	37
50	Cerebral cholesterol granuloma in homozygous familial hypercholesterolemia. Cmaj, 2005, 172, 495-497.	2.0	16
51	Cholesterol and phospholipid efflux from cultured cells. Methods, 2005, 36, 196-206.	3.8	12
52	Nuclear Receptors and the Control of Metabolism. Annual Review of Physiology, 2003, 65, 261-311.	13.1	551
53	PPAR agonists in the treatment of atherosclerosis. Current Opinion in Pharmacology, 2003, 3, 186-191.	3.5	73
54	Impaired ABCA1-dependent Lipid Efflux and Hypoalphalipoproteinemia in Human Niemann-Pick type C Disease. Journal of Biological Chemistry, 2003, 278, 32569-32577.	3.4	126

#	Article	IF	Citations
55	PPAR-Î± effects on the heart and other vascular tissues. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H1-H9.	3.2	75
56	Niemann-Pick C1 protein regulates cholesterol transport to the trans-Golgi network and plasma membrane caveolae. Journal of Lipid Research, 2002, 43, 579-589.	4.2	71
57	Niemann-Pick C1 protein regulates cholesterol transport to the trans-Golgi network and plasma membrane caveolae. Journal of Lipid Research, 2002, 43, 579-89.	4.2	62
58	Targeting HDL-mediated cellular cholesterol efflux for the treatment and prevention of atherosclerosis. Clinica Chimica Acta, 1999, 286, 219-230.	1.1	25
59	Apolipoprotein AI Efficiently Binds to and Mediates Cholesterol and Phospholipid Efflux from Human but Not Rat Aortic Smooth Muscle Cellsâ€. Biochemistry, 1999, 38, 16315-16322.	2.5	22
60	Oxidative Tyrosylation of HDL Enhances the Depletion of Cellular Cholesteryl Esters by a Mechanism Independent of Passive Sterol Desorptionâ€. Biochemistry, 1996, 35, 15188-15197.	2.5	60
61	Smooth Muscle Cellâ€"Macrophage Interactions Leading to Foam Cell Formation in Atherosclerosis: Location, Location, Location. Frontiers in Physiology, 0, 13, .	2.8	17